1例抗MDA5阳性皮肌炎患者难治性间质性肺疾病在换用托法替布后病情改善 - Suppr

Suppr

超能文献

A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.

作者信息

Hosokawa Yohei, Oiwa Hiroshi

机构信息

From the Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital.

出版信息

J Clin Rheumatol. 2021 Dec 1;27(8S):S661-S662. doi: 10.1097/RHU.0000000000001645.

DOI:10.1097/RHU.0000000000001645

PMID:33252394

Abstract

摘要

相似文献

A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.

J Clin Rheumatol. 2021 Dec 1;27(8S):S661-S662. doi: 10.1097/RHU.0000000000001645.

Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.

J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577. doi: 10.1097/RHU.0000000000000984.

Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.

Clin Immunol. 2020 Jun;215:108451. doi: 10.1016/j.clim.2020.108451. Epub 2020 Apr 29.

Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.

Ann Rheum Dis. 2023 Nov;82(11):1499-1501. doi: 10.1136/ard-2023-223919. Epub 2023 Jun 6.

Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.

Mod Rheumatol. 2022 Jan 5;32(1):231-237. doi: 10.1080/14397595.2021.1906505.

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.

Eur J Med Res. 2022 May 15;27(1):68. doi: 10.1186/s40001-022-00693-0.

Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.

Joint Bone Spine. 2022 Nov;89(6):105456. doi: 10.1016/j.jbspin.2022.105456. Epub 2022 Sep 13.

Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.

Mod Rheumatol Case Rep. 2021 Jan;5(1):76-81. doi: 10.1080/24725625.2020.1816674. Epub 2020 Sep 14.

Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation.

Intern Med. 2024 Jan 1;63(1):131-134. doi: 10.2169/internalmedicine.1621-23. Epub 2023 May 17.

Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease.

BMJ Case Rep. 2020 Apr 29;13(4):e235493. doi: 10.1136/bcr-2020-235493.

引用本文的文献

The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets.

Front Immunol. 2025 Mar 20;16:1567833. doi: 10.3389/fimmu.2025.1567833. eCollection 2025.

Clinical Characteristics and Outcomes of Patients with Anti-MDA5 Antibody Associated Rapidly Progressive Interstitial Lung Disease (RP-ILD): A Case Series.

Mediterr J Rheumatol. 2024 Dec 31;35(4):668-679. doi: 10.31138/mjr.020324.cco. eCollection 2024 Dec.

Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.

Expert Opin Pharmacother. 2024 Aug;25(12):1625-1645. doi: 10.1080/14656566.2024.2392021. Epub 2024 Aug 18.

Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis.

Skin Res Technol. 2024 May;30(5):e13701. doi: 10.1111/srt.13701.

Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease.

Rheumatol Int. 2024 May;44(5):961-971. doi: 10.1007/s00296-024-05551-2. Epub 2024 Mar 8.

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.

Intern Med. 2024 Sep 15;63(18):2571-2578. doi: 10.2169/internalmedicine.2915-23. Epub 2024 Feb 12.

Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.

Nat Rev Rheumatol. 2024 Jan;20(1):48-62. doi: 10.1038/s41584-023-01054-9. Epub 2023 Dec 6.

Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis.

Clin Rheumatol. 2023 Jul;42(7):1847-1853. doi: 10.1007/s10067-023-06567-y. Epub 2023 Mar 16.

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.

RMD Open. 2023 Jan;9(1). doi: 10.1136/rmdopen-2022-002795.

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction.

SAGE Open Med Case Rep. 2022 Dec 5;10:2050313X221141277. doi: 10.1177/2050313X221141277. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验